Headlines

Ceva Animal Health hits $10 billion valuation, eyes IPO

Published by Global Banking & Finance Review

Posted on March 31, 2025

2 min read

· Last updated: January 24, 2026

Add as preferred source on Google
Police response to shooting incident in Times Square, New York - Global Banking & Finance Review
Emergency response at Times Square following a shooting that left three individuals injured. This incident highlights ongoing gun violence issues in the US.
Global Banking & Finance Awards 2026 — Call for Entries

By Sybille de La Hamaide PARIS (Reuters) -France's Ceva Animal Health has raised 5.5 billion euros ($5.95 billion) in equity, boosting its valuation to 9.2 billion euros, as shareholders including the

Ceva Animal Health Considers IPO After $10 Billion Valuation

By Sybille de La Hamaide

PARIS (Reuters) -France's Ceva Animal Health has raised 5.5 billion euros ($5.95 billion) in equity, boosting its valuation to 9.2 billion euros, as shareholders including the billionaire Bettencourt-Meyers family increased their stake, its chief executive said on Monday.

Ceva, fifth-ranked in animal health worldwide by revenue, is known for its focus on vaccines and preventive medicine.

The Bettencourt-Meyers family, heirs to the founder of cosmetic giant L'Oreal and the largest shareholder in the company, doubled its investment in Ceva through their Tethys Invest holding.

Other large shareholders boosted their stake, including the Merieux family and Canada's pension fund PSP Investments, Ceva CEO Marc Prikazsky told Reuters.

The latest fundraising is part of a regular refinancing plan organised by the company every four to five years.

"In five years we'll reshuffle the cards. Maybe we'll go public," Prikazsky said.

"The company being much bigger and having more visibility on the stock exchange could be a good option," the CEO added, stressing that Ceva's aim was to become the world's leader in animal health.

Ceva's competitors include U.S. companies Zoetis and Merck Animal Health, and Germany's Boehringer Ingelheim.

Other investors such as Singapore's state investment company Temasek also renewed its commitment to Ceva while French healthcare focused investment firm Archimed joined the group.

Based in southwestern France but operating in 47 countries, Ceva reported revenue of 1.77 billion euros ($1.91 billion) in 2024.

The company was one of the several approached by the U.S. government, which said it was looking at vaccination as one option to contain a severe outbreak of the bird flu virus that led to the culling of millions of birds and sent egg prices soaring.

Ceva's bird flu vaccine is one of the two, along with Boehringer Ingelheim's, picked by the French government for its nationwide bird flu vaccination campaign.

($1 = 0.9249 euros)

($1 = 0.9258 euros)

(Reporting by Sybille de La Hamaide; Editing by Bill Berkrot)

Key Takeaways

  • Ceva Animal Health valued at $10 billion after equity raise.
  • Bettencourt-Meyers family doubles investment in Ceva.
  • Ceva plans potential IPO to increase market visibility.
  • Ceva's bird flu vaccine selected for French campaign.
  • Ceva operates in 47 countries with strong revenue growth.

Frequently Asked Questions

What is the main topic?
The article discusses Ceva Animal Health's $10 billion valuation and its potential IPO plans.
Who are the major investors in Ceva?
Major investors include the Bettencourt-Meyers family, the Merieux family, and Canada's PSP Investments.
What is Ceva's role in the bird flu vaccination campaign?
Ceva's bird flu vaccine is selected by the French government for a nationwide vaccination campaign.

Related Articles

More from Headlines

Explore more articles in the Headlines category